Futeng Bio Advances into the Billion-Dollar Pet Pharmaceutical Market with Dual Strategy of Innovative Drugs and Supplements

The pet industry has reached a new turning point.

According to the "2025 White Paper on China's Pet Industry (Consumer Report)," the consumer market size for urban dogs and cats grew by 7.5% in 2024, reaching RMB 300.2 billion, demonstrating a capacity for "counter-cyclical growth."

Meanwhile, as a blue-ocean market, pet healthcare offers substantial growth potential due to its currently low market penetration. Among the various segments of the pet industry, pet pharmaceuticals are regarded as key to unlocking new opportunities in the pet sector, owing to their high technical barriers, urgent market demand, and consumer-driven nature. Today, this market’s potential is continuously being realized, with new players emerging. One such participant is Shenzhen Futeng Biotechnology Co., Ltd. (hereinafter referred to as “Futeng Biotech”), which is dedicated to improving pets’ quality of life and extending their lifespan.

The research and development of veterinary pharmaceuticals and medical devices represents a market entry opportunity in China that is currently characterized by relatively weak capabilities and low market share.

Since the turn of the millennium, China’s regulatory policies related to veterinary drugs have undergone rapid development and continuous improvement. The Regulations on the Administration of Veterinary Drugs have been revised multiple times, establishing strict standards across the entire supply chain, including production, research and development, distribution, and supervision. However, prior to 2010, there were very few domestic enterprises specializing in the production of pharmaceuticals for pets.

Most veterinary drug manufacturers in China address the production of pet medications merely by extending existing production lines or restructuring their pet drug manufacturing divisions. Consequently, R&D-focused enterprises in the domestic pet pharmaceutical sector are predominantly concentrated on vaccine development, resulting in highly overlapping product portfolios with limited differentiation. Furthermore, the relatively small scale of pet drug production and the narrow range of available formulations fail to meet the urgent demand for diverse, specialized medications driven by the rapid growth of the pet industry.

To alleviate the clinical supply-demand imbalance in pet medications, the Ministry of Agriculture and Rural Affairs is accelerating the registration process for veterinary drugs intended for pets and has issued Announcement No. 330, which specifies the "Requirements for Registration Materials for the Conversion of Human Chemical Drugs to Pet Chemical Drugs." Since then, research and development in the pet pharmaceutical sector has surged, with domestic pharmaceutical companies actively entering this market.

Futeng Bio was established against this backdrop. During its development, the Futeng Bio team recognized the predicament of having no available treatments for conditions such as chronic kidney disease in pets and resolved to apply their expertise. They adapted their R&D experience from the human pharmaceutical sector to the development of veterinary drugs, tailoring their approach to the specific needs of the field.

Founding Team MembersAll hail from the biomedical sector, with many holding degrees from top-tier institutions such as Fudan University and Tsinghua University. They possess profound expertise in specialized fields including microbiology and microbial and biochemical pharmacy, have published multiple high-impact SCI papers in prestigious international journals such as Emerging Microbes & Infections and ACS Nano, and have achieved numerous scientific research accomplishments in their respective areas, thereby laying a solid foundation for the company’s R&D efforts.

Furthermore, the team members possess over 10 years of experience in pharmaceutical R&D and management, having been fully involved in and familiar with the entire process from drug development to clinical trials for multiple products. The head of sales and marketing has cultivated deep expertise in the pet market sector for many years, having previously worked at renowned companies such as Zoetis and Royal Canin, thereby accumulating extensive professional networks and resources. Meanwhile, the company’s technical advisor brings more than a decade of experience in basic and translational research on kidney diseases. They have published over 20 SCI-indexed papers in prestigious international journals, including Nature Communications and EMBO Reports, as first or co-first author, and have successfully secured more than five patents related to drug translation.

Navigating an immature sector inevitably entails a path fraught with thorns. Yet, it is precisely the company’s team thatLong-term exploration in the construction of cell and animal models for indications such as chronic kidney disease, central nervous system (CNS) disorders, and aging, along with extensive clinical data from veterinary practice, ensuring that Futeng Bio receives support and safeguards at every stage.

Futeng Bio has conducted extensive, long-term exploration in the development of cellular and animal models for indications such as chronic kidney disease, central nervous system (CNS) disorders, and aging. Meanwhile, by conducting visits and surveys at veterinary hospitals in the Chengdu-Chongqing region and the Greater Bay Area, the company has accumulated substantial clinical data from companion animals, thereby securing a solid foundation for its drug R&D efforts.

Supported by core technologies, the company has formulated a “One Body, Two Wings” development strategy, namelyBuild a pipeline of innovative pet drugs (with high technical barriers) and an animal health products pipeline (as a cash flow business)thereby ensuring the company's sustained and robust development.

Chronic kidney disease (CKD) refers to chronic conditions that cause permanent damage to animal kidneys and is one of the key strategic focus areas for Futeng Bio.

This disease is particularly common in geriatric animals, with a higher incidence in cats than in dogs. Affected animals often exhibit clinical signs such as emaciation, anemia, lethargy, vomiting, polyuria, and polydipsia. Chronic kidney disease (CKD) is staged from I to IV based on the severity of renal damage; when the disease progresses to Stage III (loss of ≥75% of nephron function), it further deteriorates into azotemia.

Epidemiological data indicate that approximately one-third of cats over the age of 10 suffer from chronic kidney disease (CKD), while about one in ten dogs will develop this condition during their lifetime. However, current management of CKD primarily relies on supportive care strategies, such as the use of diuretics and antibiotics, with a notable lack of effective, disease-specific therapeutic agents.

Futeng Bio recognizes the critical impact of chronic kidney disease (CKD) on pet health. After an in-depth analysis of clinical needs, the company has designated CKD as a key focus area within its pipeline for companion animal chronic diseases and prioritized it as a central R&D direction. The technical foundation for this CKD pipeline is supported by the extensive experience in nephrology drug development accumulated by the core team members during their doctoral studies and professional careers.

When Selecting a Chronic Kidney Disease Model, Futeng Biology engaged in thorough communication with clinical veterinary hospitals to select the model with the highest species compatibility for drug development, thereby ensuring the accuracy and reliability of the research. During the drug development process, various kidney disease modeling techniques were fully utilized, including cell models, organoid models, and mouse/rat models. Drug screening and evaluation were conducted using injury models induced by agents such as cisplatin and folic acid, simulated ischemia-reperfusion injury models induced by hypoxia-reoxygenation and cobalt chloride, as well as kidney organoid models constructed from induced pluripotent stem cells.

Furthermore, the company has developed specific mouse models based on the Flox-Ksp-Cre system and utilized drug-induced kidney injury models involving cisplatin and gentamicin to solidify the foundation for chronic kidney disease drug development.

In terms of drug screening logicFuteng Bio adheres to a product development strategy that originates from and returns to clinical practice. By integrating high-throughput data from bioinformatics, transcriptomics, and proteomics, the company analyzed key targets in chronic kidney disease (CKD) in pets and identified critical molecular targets regulating the progression of CKD in dogs and cats. Subsequently, through cell-level and animal-level experimental validation, as well as drug screening using molecular docking software, the company ultimately obtained multiple potential candidate drugs for treating chronic kidney disease in pets.

It is worth emphasizing that,Chronic kidney disease is the therapeutic area with the most robust pipeline of preclinical candidate (PCC) molecules for the company at present.The continuous optimization of AlphaFold2 and AlphaFold3 in protein structure prediction and protein-protein interaction (PPI) prediction has facilitated the company’s drug development efforts. By simulating PPIs involving key pathogenic proteins during the onset and progression of chronic kidney disease in pets, preclinical studies on multiple candidate natural small molecules and short peptides have been completed, and formulation process development for certain Preclinical Candidate (PCC) molecules has also been finalized.

Furthermore,The company’s research findings have been published in prestigious journals, including Nature Communications, Journal of Molecular Cell Biology, ACS Nano, and Gut Microbes, and the potential of its core targets has been validated.Subsequently, the company will accelerate the application for clinical trial approval.

In addition to its chronic kidney disease pipeline, Futeng Biopharma is continuously expanding its innovative drug pipeline.R&D of Anti-Aging Products and Muscle Mass Improvement Drugs for Pets, to meet the increasingly diverse needs of pet owners regarding their pets' health.

In the area of anti-aging products, the company has identified its therapeutic targets and drug molecules and is currently conducting preclinical animal studies for validation. Compared with NMN-dominated pet anti-aging products on the market, the company’s drug molecule is a natural small-molecule compound that offers superior stability and bioavailability, holding promise to deliver longer and healthier lives for pets.

Meanwhile, the company has made significant progress in developing drugs for improving muscle mass. Preclinical trials have been completed, and the drug is currently undergoing formulation development and preparation for clinical trial validation. This product targets fibro/adipogenic progenitor (FAP) cells, inhibiting their accumulation in injured or atrophied muscle tissue, while enhancing the ability of FAP cells to support muscle stem cell activation, thereby effectively promoting muscle regeneration.

Furthermore, the company has keenly identified market demand for addressing separation anxiety in pets. Leveraging its own pet-ownership experience and market research analysis, it established a development pipeline focused on separation anxiety and developed a natural small-molecule product targeting GABA. By crossing the blood-brain barrier to act on cerebral GABA, this product alleviates anxiety in pets. Its well-defined molecular mechanism and ingredients that are both food-grade and medicinal ensure the product’s safety and efficacy.

Notably, to ensure the palatability and bioavailability of pet health supplements and meet the diverse needs of different pets, the company has adopted specially developed formulation technologies. These technologies enhance the solubility of active ingredients, as well as the stability and bioavailability of the formulations, thereby accelerating product commercialization and sales.

According to the company, its pipeline for separation anxiety is currently the most advanced, with an expected market launch between late 2024 and early 2025. Meanwhile, the company’s pipeline of anti-aging health supplements is either in the R&D phase or included in sales planning.

Overall, China’s pet industry suffers from a severe shortage of veterinary medical services and pharmaceuticals. This is manifested in a limited variety of drug offerings and a scarcity of therapeutics for major diseases, failing to meet the diverse clinical medication needs. Furthermore, there are few domestic enterprises dedicated to the research and development of pet pharmaceuticals, with innovation capabilities requiring enhancement and product portfolios needing further diversification and expansion.

In contrast, the U.S. pet pharmaceutical market already has approximately 400 drugs approved for use in dogs and cats, encompassing specialized products such as anti-motion sickness medications, antidepressants, weight-loss drugs, and contraceptives. Although China’s pet pharmaceutical industry is still in its early stages of rapid development, the accelerating trend of pet aging is increasingly highlighting the demand for therapeutic agents targeting digestive disorders, metabolic diseases, cardiovascular and cerebrovascular conditions, endocrine disorders, and neurological diseases, thereby presenting substantial market potential.

In the future, Futeng Bio will remain committed to its core pipeline, continuously strengthen its R&D capabilities, adopt appropriate sales strategies, and accelerate product commercialization.